Tumor suppressor activity of CBX7 in lung carcinogenesis

Cell Cycle

Volumn 11, Issue 10, 2012, Pages 1888-1891

  Forzati, Floriana ^a   Federico, Antonella ^a   Pallante, Pierlorenzo ^a   Fedele, Monica ^a   Fusco, Alfredo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

CBX7; Cyclin E; HMGA1; KO mice; Wng tumor

Indexed keywords

CYCLIN E;

CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CBX7 GENE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; COLON CARCINOMA; EXON; GENE EXPRESSION; HUMAN; HYPERPLASIA; LIVER CARCINOMA; LUNG CARCINOGENESIS; LUNG CARCINOMA; NONHUMAN; PHENOTYPE; PROMOTER REGION; REVIEW; TUMOR SUPPRESSOR GENE; UPREGULATION;

MUS;

EID: 84861417712     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20022     Document Type: Review

References (28)

1. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 2004; 118:409-18; PMID:15315754; http:// dx.doi.org/10.1016/j.cell.2004.08.005.
2. Gil J, Bernard D, Martínez D, Beach D. Polycomb CBX7 has a unifying role in cellular lifespan. Nat Cell Biol 2004; 6:67-72; PMID:14647293; http:// dx.doi.org/10.1038/ncb1077.
3. Bernstein E, Duncan EM, Masui O, Gil J, Heard E, Allis CD. Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. Mol Cell Biol 2006; 26:2560-9; PMID:16537902; http://dx.doi.org/10.1128/MCB.26.7.2560-9.2006.
4. Lund AH, van Lohuizen M. Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 2004; 16:239-46; PMID:15145347; http://dx.doi. org/10.1016/j.ceb.2004.03.010.
5. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 2009; 9:773-84; PMID:19851313; http://dx.doi.org/10.1038/nrc2736.
6. Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA, et al. Integrative genomics analysis reveals silencing of β-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 2007; 12:419-31; PMID:17996646; http://dx.doi.org/10.1016/j.ccr.2007.10.016.
7. Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007; 67:10657-63; PMID:18006806; http://dx.doi. org/10.1158/0008- 5472.CAN-07-2498.
8. Pallante P, Federico A, Berlingieri MT, Bianco M, Ferraro A, Forzati F, et al. Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res 2008; 68:6770-8; PMID:18701502; http://dx.doi.org/10.1158/0008-5472.CAN-08-0695.
9. Pallante P, Terracciano L, Carafa V, Schneider S, Zlobec I, Lugli A, et al. The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur J Cancer 2010; 46:2304-13; PMID:20542683; http://dx.doi. org/10.1016/j.ejca.2010.05.011.
10. Hinz S, Kempkensteffen C, Christoph F, Krause H, Schrader M, Schostak M, et al. Expression parameters of the polycomb group proteins BMI1, SUZ12, RING1 and CBX7 in urothelial carcinoma of the bladder and their prognostic relevance. Tumour Biol 2008; 29:323-9; PMID:18984978; http://dx.doi. org/10.1159/000170879.
11. Karamitopoulou E, Pallante P, Zlobec I, Tornillo L, Carafa V, Schaffner T, et al. Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer 2010; 46:1438-44; PMID:20185297; http://dx.doi. org/10.1016/j.ejca.2010.01.033.
12. Mansueto G, Forzati F, Ferraro A, Pallante P, Bianco M, Esposito F, et al. Identification of a new pathway for tumor progression: microRNA-181b upregulation and CBX7 downregulation by HMGA1 protein. Genes Cancer 2010; 1:210-24; PMID:21779448; http://dx.doi.org/10.1177/1947601910366860.
13. Jiang Z, Guo J, Xiao B, Miao Y, Huang R, Li D, et al. Increased expression of miR-421 in human gastric carcinoma and its clinical association. J Gastroenterol 2010; 45:17-23; PMID:19802518; http://dx.doi. org/10.1007/s00535-009-0135-6.
14. Forzati F, Federico A, Pallante P, Abbate A, Esposito F, Malapelle U, et al. CBX7 is a tumor suppressor in mice and humans. J Clin Invest 2012; 122:612- 23; PMID:22214847; http://dx.doi.org/10.1172/ JCI58620.
15. Scott CL, Gil J, Hernando E, Teruya-Feldstein J, Narita M, Martínez D, et al. Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci USA 2007; 104:5389-94; PMID:17374722; http://dx.doi.org/10. 1073/pnas.0608721104.
16. Federico A, Pallante P, Bianco M, Ferraro A, Esposito F, Monti M, et al. Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. Cancer Res 2009; 69:7079-87; PMID:19706751; http://dx.doi.org/10.1158/0008-5472.CAN-09- 1542.
17. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2:442- 54; PMID:12189386; http://dx.doi.org/10.1038/ nrc822.
18. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7:131-42; PMID:16493418; http:// dx.doi.org/10.1038/nrm1835.
19. Boye K, Maelandsmo GM. S100A4 and metastasis: a small actor playing many roles. Am J Pathol 2010; 176:528-35; PMID:20019188; http://dx.doi. org/10.2353/ajpath.2010.090526.
20. Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med 2010; 10:71-81; PMID:20205680; http:// dx.doi.org/10.2174/156652410791065381.
21. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res 1999; 59:2470-6; PMID:10344760.
22. Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, et al. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci USA 2007; 104:4089-94; PMID:17360482; http://dx.doi.org/10.1073/pnas. 0606537104.
23. Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci USA 1996; 93:15215-20; PMID:8986790; http://dx.doi. org/10.1073/pnas.93.26. 15215.
24. Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res 2010; 70:5074-84; PMID:20530685; http://dx.doi.org/10.1158/0008-5472.CAN-09- 4094.
25. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009; 6:201-5; PMID:19349489; http://dx.doi. org/10.1513/pats.200809-107LC.
26. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003; 4:111-20; PMID:12957286; http://dx.doi.org/10.1016/ S1535- 6108(03)00191-0.
27. Bernard D, Martinez-Leal JF, Rizzo S, Martinez D, Hudson D, Visakorpi T, et al. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene 2005; 24:5543-51; PMID:15897876; http://dx.doi. org/10.1038/sj.onc.1208735.
28. Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011; 117:2451-9; PMID:21190999; http://dx.doi.org/10.1182/blood- 2010-11-321208.